medigraphic.com
ISSN 1561-2945 (Print)

2022, Number 2

<< Back Next >>

Revista Cubana de Cirugía 2022; 61 (2)

Results of treating of anal cancer patients at comandante ''Manuel Fajardo'' Surgical Clinical University Hospital

Gutiérrez AK, Llorente LFF, Vega GM, Vidal PD

Language: Spanish
References: 20
Page: 1-13
PDF size: 430.76 Kb.


ABSTRACT

Introduction: Anal cancer is the one with the lowest incidence of the digestive tract, but in recent years it has slightly increased.
Objective: To identify the results of the treatment used for anal cancer in the Coloproctology Service of Comandante Manuel Fajardo Surgical Clinical University Hospital.
Methods: A descriptive and observational study was carried out with patients diagnosed and treated for anal cancer in the 2014-2019 period. Variables such as pathological history, risk factors, symptoms, stage of the disease, treatments, among others, were studied.
Results: The mean age was 58.4 ± 14.7 years and 75.3% were women. 52.1% had pathological antecedents and the most frequent risk factor was age (> 50 years: 80.8%). The most usual location was in the anal canal and stages II and III. Bleeding appeared in 58.9% of the patients. Chemoradiation therapy (87.7%), local exeresis (17.8%) and abdominoperineal surgery (8.2%) were applied. Colostomy was performed in 14% of individuals; 72.6% were free of colostomy for more than one year. The colostomy-free time was 87.5%, with treatment of 5 years and more. 24.7% died, the disease progression was the cause of death in 55.6% of the diseased subjects, while the most frequent cause was liver metastasis.
Conclusions: Chemoradiotherapy was the main treatment with which an acceptable survival rate was obtained in patients with anal cancer.


REFERENCES

  1. Osma HR, Bonilla CE, Oliveros R, Vargas HA, Beltrán JA, Melo MA, et al. Carcinoma escamocelular del canal anal metastásico en un paciente con VIH tratado con quimiorradioterapia concomitante. Reporte de un caso y revisión de la literatura. Rev Colomb Gastroenterol. 2019;34(4):438-444. DOI: https://doi.org/10.22516/25007440.2901.

  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68:394-424.

  3. Hernández Delgado S. La citología: un instrumento de utilidad en el diagnóstico precoz del cáncer anal. Medisur. 2018;16(1):7-9.

  4. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2020. Anal Carcinoma. 2019.

  5. Nigro ND. An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum. 1984;27(12):763-6.

  6. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4.

  7. Kang Y-J, Smith M, Canfell K. Anal cancer in high-income countries: Increasing burden of disease. PLoS ONE. 2018;13(10):e0205105.

  8. Dale JE, Sebjørnsen S, Leh S, Rösler C, Aaserud S, Møller B, et al. Multimodal therapy is feasible in elderly anal cancer patients, Acta Oncológica. 2017;56(1):81-87.

  9. Symer MM, Yeo HL. Recent advances in the management of anal cancer. F1000Research 2018, 7(F1000 Faculty Rev):1572. DOI: 10.12688/f1000research.14518.1.

  10. Ministerio de Salud Pública. Anuario estadístico de salud, 2019. Dirección nacional de registros médicos y estadísticas de salud. La Habana: Cuba; 2020.

  11. Dalla Libera LS, Almeida de Carvalho KP, Porto Ramos JE, Oliveira Cabral LA, Goncalves de Alencar RC, Lina Villa L, et al. Human Papillomavirus and Anal Cancer: Prevalence, Genotype Distribution, and Prognosis Aspects from Midwestern Region of Brazil Journal of Oncology. 2019. DOI: https://doi.org/10.1155/2019/601826911. .

  12. Oficina Nacional de estadísticas e información. El color de la piel según el Censo de población y vivienda de 2012; Feb 2016.

  13. Llorente Llano FF, Rengifo González C. Prevalencia de infección anal por el virus del papiloma humano en el Hospital "Comandante Manuel Fajardo". Rev Cubana de Cir. 2017;56(1):27-36.

  14. Valvo F, Ciurlia E, Avuzzi B, Doci R, Ducreux M, Roelofsene F, et al. Cancer of the anal región. Critical Reviews in Oncology / Hematology. 2019;135:115-27.

  15. Sauter M, Keilholz G, Kranzbühler H, Lombriser N, Prakash M, Vavricka SR, et al. Presenting symptoms predict local staging of anal cancer: a retrospective analysis of 86 patients. BMC Gastroenterology. 2016;16:46.

  16. Chakrabarti S, Jin Z, Huffman BM, Yadav S, Graham RP, Lam-Himlin DM, et al. Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. J Gastrointest Oncol. 2019;10(2):171-8.

  17. Eng C, Messick C, Glynne-Jones R. The Management and Prevention of Anal Squamous Cell Carcinoma. ASCO EDUCATIONAL BOOK. 2019. DOI: https://doi.org/10.1200/EDBK_23743317.

  18. Chai CY, Cao HT, Awad S, Massarweh NN. Management of Stage I Squamous Cell Carcinoma of the Anal Canal. JAMA Surg. 2018;153(3):209-15.

  19. Ghosn M, Kourie HR, Abdayem P, Antoun J, Nasr J. Anal cancer treatment: current status and future perspectives. World J Gastroenterol. 2015;21(8):2294-302.

  20. National Cancer Institute. Surveillance, Epidemiology and Results Program U. Seer, National Cancer Institute, Bethesda. 2018 [acceso 22/09/2021]. Disponible en: https://seer.cancer.gov/statfacts/html/anus.html20.




2020     |     www.medigraphic.com